September 10, 2025

Clinical analysis of donor-purified CD34(+) stem cell boost in 11 patients with poor hematopoietic reconstruction after haploid hematopoietic stem cell transplantation for aplastic anemia.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis shows improved outcomes with CD34(+) stem cell boosts in patients post-haplo-HSCT, indicating potential therapeutic benefits.

Donor-purified CD34(+) stem cell boost improved hematopoietic recovery in patients with aplastic anemia after haplo-HSCT.
Twenty-two days post-infusion, two patients with isolated thrombocytopenia achieved complete recovery, while six out of nine with PGF fully recovered.
The analysis included 11 patients, showing an overall survival rate of 90.9% with a median follow-up of 614 days.
Chronic graft-versus-host disease incidence was 18.2%, indicating a favorable safety profile of the intervention.

He et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis shows improved outcomes with CD34(+) stem cell boosts in patients post-haplo-HSCT, indicating potential therapeutic benefits.